Skip to main content

Table 2 Change in tumour perfusion, FDG-SUV, clinical benefit, and pharmacokinetic and pharmacodynamic parameters following sunitinib treatment

From: Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies

Patient

Baseline perfusion (mL/min/g)

Change in perfusion (%)

Baseline FDG-SUV

Change in FDG-SUV at week 2 (%)

Change in FDG-SUV at week 4 (%)

Clinical benefit a

Day 15 trough levels of sunitinib +  SU12662 b (ng/mL)

VEGF plasma levels D15:D1

sVEGFR-2 plasma levels D15:D1

1

0.81

−85

4.6

−39

−48

Yes

76.4

5.29

0.66

2

1.18

−77

6.5

−37

−59

Yes

134.9

4.85

0.44

3

1.52

−59

4.2

−33

−29

No

90.8

8.67

0.34

4

1.28

−34

9.8

−44

−13

No

27.6

2.56

0.75

5

0.74

−69

12.3

−67

−66

Yes

107.1

4.17

0.49

6

1.39

−38

6.0

−32

−18

Yes

88.8

NA

NA

7

1.23

−20

4.1

−29

−41

No

105.0

NA

NA

  1. aClinical benefit was deemed to be present if the treating clinician judged that the patient was benefiting from treatment and continued therapy beyond the 12-week study period. bTarget trough level for therapeutic effect was considered > 50 ng/mL. D15:D1, day 15:day 1 ratio; FDG-SUV, 18 F-fluorodeoxyglucose standard uptake value; NA, not available; VEGF, vascular endothelial growth factor; sVEGFR-2, soluble vascular endothelial growth factor receptor 2.